Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RADIANCE: Radscopal Radiotherapy Plus Dual Immunotherapy in Chemotherapy-Ineligible De Novo Metastatic Nasopharyngeal Carcinoma
ChiCTR2600130265Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab and ipilimumab in nasopharyngeal carcinoma (NPC), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Objective Response Rate of Primary Nasopharyngeal Lesion (ORR). Planned start Aug 2026; status: not yet recruiting.
02
Drugs
sintilimabipilimumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR2600130265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600130265.